STAAR Surgical Company (STAA)
- Previous Close
42.62 - Open
42.82 - Bid 42.67 x 100
- Ask 42.80 x 100
- Day's Range
42.06 - 43.71 - 52 Week Range
26.66 - 65.06 - Volume
318,669 - Avg. Volume
686,179 - Market Cap (intraday)
2.098B - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
137.74 - EPS (TTM)
0.31 - Earnings Date Jul 31, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
51.50
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
www.staar.com1,056
Full Time Employees
December 29
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: STAA
Performance Overview: STAA
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STAA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STAA
Valuation Measures
Market Cap
2.10B
Enterprise Value
1.89B
Trailing P/E
137.74
Forward P/E
131.58
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.45
Price/Book (mrq)
5.34
Enterprise Value/Revenue
5.79
Enterprise Value/EBITDA
66.83
Financial Highlights
Profitability and Income Statement
Profit Margin
4.69%
Return on Assets (ttm)
3.38%
Return on Equity (ttm)
4.18%
Revenue (ttm)
326.24M
Net Income Avi to Common (ttm)
15.3M
Diluted EPS (ttm)
0.31
Balance Sheet and Cash Flow
Total Cash (mrq)
245.15M
Total Debt/Equity (mrq)
9.09%
Levered Free Cash Flow (ttm)
27.15M
Research Analysis: STAA
Company Insights: STAA
STAA does not have Company Insights